The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy during first line with cetuximab in KRAS wild-type metastatic colorectal cancer (mCRC): Results of a large prospective multicenter cohort carried out by the premium French observational study.
Laurent Mineur
No relevant relationships to disclose
Gilles Seni
No relevant relationships to disclose
Laurent Miglianico
No relevant relationships to disclose
louis-Marie Dourthe
No relevant relationships to disclose
Nathalie Bonichon
No relevant relationships to disclose
Lionel Moreau
No relevant relationships to disclose
Rosine Guimbaud
No relevant relationships to disclose
Denis Smith
No relevant relationships to disclose
Emmanuel Achille
No relevant relationships to disclose
Robert Herve
No relevant relationships to disclose
Jean Michel Bons
No relevant relationships to disclose
Stephane Remy
No relevant relationships to disclose
jean Pierre Daures
No relevant relationships to disclose